Premium
UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN‐LABEL, REGISTRATION DIRECTED PHASE 2 STUDY
Author(s) -
Zinzani P.,
Samaniego F.,
Jurczak W.,
LechMaranda E.,
Ghosh N.,
Anz B.,
Patten P.,
Reeves J.,
Leslie L.A.,
Smolewski P.,
Chavez J.C.,
Scarfo L.,
Derenzini E.,
Burke J.M.,
Sharman J.,
Kolibaba K.,
O'Connor O.A.,
Cheah C.Y.,
Miskin H.P.,
Sportelli P.,
Weiss M.S.,
Fowler N.H.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - Slovenian
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.139_2629
Subject(s) - medicine , refractory (planetary science) , open label , phases of clinical research , oncology , clinical trial , biology , astrobiology
133 UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN-LABEL, REGISTRATION DIRECTED PHASE 2 STUDY P. Zinzani | F. Samaniego | W. Jurczak | E. Lech-Maranda | N. Ghosh | B. Anz | P. Patten | J. Reeves | L.A. Leslie | P. Smolewski | J.C. Chavez | L. Scarfo | E. Derenzini | J.M. Burke | J. Sharman | K. Kolibaba | O.A. O'Connor | C.Y. Cheah | H.P. Miskin | P. Sportelli | M.S. Weiss | N.H. Fowler